Immutep

Immutep is listed on the Australian Stock Exchange (ASX:IMM) and on the NASDAQ Global Market (NASDAQ:IMMP) in the U.S. (ADR's).

We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.

We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.

Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.

Email Alerts for:
ASX:IMM

Latest Media Releases

Immutep - Excellent Survival Data from INSIGHT-003 Trial in NSCLC

-- Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: ---- Median Overall Survival is 32.9…

Immutep - Positive Data from Phase II Trial in Soft Tissue Sarcoma

-- Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma -- Over three-fold increase in tumour hy…

Immutep Quarterly Activities Report and Appendix 4C

Key points: Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the …

Latest News

ASX closes 0.78% higher to wrap up a solid week of trading

31 Mar 2023 - At the closing bell, the S&P/ASX 200 was 0.78 per cent higher at 7,177.80, led by the materials sector, which saw BHP Group's (ASX:BHP) shares rise by 2.5 per cent.

Gains from materials and healthcare boost ASX 0.71% at noon

31 Mar 2023 - At noon, the S&P/ASX 200 is 0.71% higher at 7,173, with materials and healthcare sectors leading the gains. Syrah Resources (ASX:SYR), Block (ASX:SQ2), and De Grey Mi…

Stocks of the Hour: NOVONIX, Immutep, Sayona Mining

31 Mar 2023 - A snapshot of the stocks on the move featuring NOVONIX (ASX:NVX), Immutep Limited (ASX: IMM; NASDAQ:IMMP) and Sayona Mining (ASX:SYA).

ASX falls 1.4% to lowest point in three months

14 Mar 2023 - At the closing bell, the S&P/ASX 200 was 1.4 per cent lower at 7,008.9, a three-month low. The fall was mainly due to concerns about a financial crisis after the coll…

ASX sinks to lowest point since Jan: Aus shares down 1.91% at noon

14 Mar 2023 - Earlier today, the S&P/ASX 200 stock index of Australia experienced a decline of 2.1 per cent and hit a new low of 6956.7, which is close to its lowest point of the y…

Stocks of the Hour: Patrys, Mt Monger Resources, Immutep

14 Mar 2023 - A snapshot of the stocks on the move featuring Patrys (ASX:PAB), Mt Monger Resources (ASX:MTM) and Immutep (ASX:IMM).

Immutep (ASX:IMM) delivering strong data in first-line non-small cell lung cancer

01 Mar 2023 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses data from SITC, the strategy to take Efti to market and milestones for 2023.

Immutep (ASX:IMM) - Webinar Presentation

17 Feb 2023 - Marc Voigt - Executive Director and CEO - Immutep (ASX:IMM) is leading the development of immunotherapy for cancer and autoimmune diseases.

Property sector leads ASX 0.3% lower

06 Feb 2023 - Large property players Goodman Group (ASX:GMG), Dexus (ASX:DXS), Mirvac Group (ASX:MGR) and Charter Hall (ASX:CHC) have all suffered losses in today’s session.

ASX 0.1% lower at noon after all US indices fell over the weekend

06 Feb 2023 - All sectors besides Energy and Materials are trading lower today, after the US sectors fell on Friday due to a strong jobs report, which caused some investors to worr…

Aus shares lower despite a spike in US markets: ASX down 0.15% at noon

30 Jan 2023 - The global race for lithium, a commodity crucial for the electric vehicle (EV) industry, has intensified as German Chancellor Olaf Scholz signed an agreement with Arg…

Lithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower

08 Dec 2022 - Goldman Sachs have extended their bearish views on lithium, believing that the prices are expected to decline from the second half of 2023.

Lithium stocks under pressure following Goldman's comments: ASX down 0.47% at noon

08 Dec 2022 - The Australian market is still unnerved over concerns about a possible US recession. Energy is weighing down the benchmark over fears demand for oil will be impacted …

Shares dive following rate hike: ASX closes 0.5% lower

06 Dec 2022 - The ASX has closed 0.47 per cent lower after the Reserve Bank of Australia delivered its eighth interest rate hike in a row, lifting the cash rate 25 basis higher to …

Local market awaits RBA rate decision: ASX falls 0.17% at noon

06 Dec 2022 - The Australian market has followed Wall Street’s negative lead overnight after US markets sold off on fears that the Fed will keep increasing interest rates. Also wei…

Iron ore climbs to highest price since September: ASX closes 0.3% higher

29 Nov 2022 - Singaporean iron ore futures have soared above the US$100 per tonne for the first time since September, resulting in gains for ASX-listed iron ore companies.

Chinese protests over lockdowns continue: Aus shares 0.07% lower at noon

29 Nov 2022 - The global economic outlook is shaky, as growing protests in the world's largest manufacturing nation are creating a new level of uncertainty for the economy.

Immutep (ASX:IMM) discusses a transformative year for LAG-3 therapies

28 Nov 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company's portfolio of therapies, encouraging data from the 2022 SI…

Immutep (ASX:IMM) - Update on new TACTI-002 Phase II and initial INSIGHT-003 Phase 1 data presented at SITC 2022

14 Nov 2022 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Professor Frédéric Triebel, and Vice President Strategic Develop…

Market losing momentum, materials the saviour: ASX flat at noon

14 Nov 2022 - Last week’s gains have not continued with the same momentum this morning. Materials, up 3.4 per cent, is bolstering the local market following a rise in commodity pri…

A sea of red in today's trading: ASX closes 1.84% lower

03 Nov 2022 - All but one sector finished lower today, as the ASX reacted to the overnight news that the Fed has increased rates by 75 basis points.

All red across the board following US rate hike sentiment: ASX down 1.96% at noon

03 Nov 2022 - US equities plunged after Fed Chair Jerome Powell indicated policymakers would continue raising interest rates to fight persistent inflation. Markets had initially so…

ASX increases slightly ahead of today's interest rate rise: Aus shares 0.3% higher at noon

01 Nov 2022 - Last week’s rally for US equities ground to a halt overnight ahead of this week’s Federal Reserve decision on interest rates, as tech stocks weighed on the major inde…

Market unfazed by CPI data: ASX finishes 0.18% higher

26 Oct 2022 - CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise.

Australian headline inflation hits highest in 32 years: ASX up 0.12% at noon

26 Oct 2022 - The S&P/ASX 200 posted gains this morning as sentiment from Wall Street overnight improved over the Fed potentially turning less aggressive, combined with a decline i…